Articles with public access mandates - Ru M WenLearn more
Not available anywhere: 4
Drug resistance to targeted therapeutic strategies in non-small cell lung cancer
W Liu, Y Du, R Wen, M Yang, J Xu
Pharmacology & therapeutics 206, 107438, 2020
Mandates: National Natural Science Foundation of China
A prodrug of two approved drugs, cisplatin and chlorambucil, for chemo war against cancer
RK Pathak, R Wen, N Kolishetti, S Dhar
Molecular cancer therapeutics 16 (4), 625-636, 2017
Mandates: US Department of Defense, US National Institutes of Health
Synthesis of Li4Ti5O12 nanostructural anode materials with high charge–discharge capability
R Wen, J Yue, Z Ma, W Chen, X Jiang, A Yu
Chinese Science Bulletin 59, 2162-2174, 2014
Mandates: Australian Research Council
Accessing mitochondrial targets using nanocargos
R Wen, AC Umeano, S Dhar
Intracellular Delivery III: Market Entry Barriers of Nanomedicines, 229-254, 2016
Mandates: US National Institutes of Health
Available somewhere: 11
Nanoparticle‐laden macrophages for tumor‐tropic drug delivery
W Zhang, M Wang, W Tang, R Wen, S Zhou, C Lee, H Wang, W Jiang, ...
Advanced Materials 30 (50), 1805557, 2018
Mandates: US National Science Foundation, US Department of Defense, US National …
The DNA repair nuclease MRE11A functions as a mitochondrial protector and prevents T cell pyroptosis and tissue inflammation
Y Li, Y Shen, K Jin, Z Wen, W Cao, B Wu, R Wen, L Tian, GJ Berry, ...
Cell metabolism 30 (3), 477-492. e6, 2019
Mandates: US National Institutes of Health
Nanotechnology inspired tools for mitochondrial dysfunction related diseases
R Wen, B Banik, RK Pathak, A Kumar, N Kolishetti, S Dhar
Advanced drug delivery reviews 99, 52-69, 2016
Mandates: US National Institutes of Health, American Heart Association
The Platin-X series: activation, targeting, and delivery
U Basu, B Banik, R Wen, RK Pathak, S Dhar
Dalton Transactions 45 (33), 12992-13004, 2016
Mandates: US National Institutes of Health, American Heart Association
Sialylated glycoproteins as biomarkers and drivers of progression in prostate cancer
R Wen, H Zhao, D Zhang, CL Chiu, JD Brooks
Carbohydrate Research 519, 108598, 2022
Mandates: US Department of Defense, US National Institutes of Health
Mitochondrion: a promising target for nanoparticle-based vaccine delivery systems
R Wen, AC Umeano, L Francis, N Sharma, S Tundup, S Dhar
Vaccines 4 (2), 18, 2016
Mandates: US National Institutes of Health, American Heart Association
NUSAP1 binds ILF2 to modulate R-loop accumulation and DNA damage in prostate cancer
CL Chiu, CG Li, E Verschueren, RM Wen, D Zhang, CA Gordon, H Zhao, ...
International journal of molecular sciences 24 (7), 6258, 2023
Mandates: US Department of Defense, US National Institutes of Health, UK Medical …
Core hydrophobicity tuning of a self-assembled particle results in efficient lipid reduction and favorable organ distribution
B Banik, R Wen, S Marrache, A Kumar, N Kolishetti, EW Howerth, S Dhar
Nanoscale 10 (1), 366-377, 2018
Mandates: US National Institutes of Health, American Heart Association
Measuring the multifaceted roles of mucin-domain glycoproteins in cancer
NM Riley, RM Wen, CR Bertozzi, JD Brooks, SJ Pitteri
Advances in cancer research 157, 83-121, 2023
Mandates: US Department of Defense, US National Institutes of Health
Distinguishing renal cell carcinoma from Normal kidney tissue using mass spectrometry imaging combined with machine learning
V Shankar, K Vijayalakshmi, R Nolley, GA Sonn, CS Kao, H Zhao, R Wen, ...
JCO Precision Oncology 7, e2200668, 2023
Mandates: US Department of Defense, US National Institutes of Health
517 Blocking Siglec-7/9-sialic acid interactions induces immune cell-mediated suppression of prostate cancer
R Wen, J Stark, GE Marti, N Riley, H Zhao, CR Bertozzi, S Pitteri, ...
Journal for ImmunoTherapy of Cancer 11 (Suppl 1), 2023
Mandates: US Department of Defense, US National Institutes of Health
Publication and funding information is determined automatically by a computer program